225 related articles for article (PubMed ID: 22731912)
21. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.
Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H
BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579
[TBL] [Abstract][Full Text] [Related]
22. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
Tanizaki J; Okamoto I; Sakai K; Nakagawa K
Br J Cancer; 2011 Sep; 105(6):807-13. PubMed ID: 21847121
[TBL] [Abstract][Full Text] [Related]
23. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
24. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
25. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
26. Disabling receptor ensembles with rationally designed interface peptidomimetics.
Berezov A; Chen J; Liu Q; Zhang HT; Greene MI; Murali R
J Biol Chem; 2002 Aug; 277(31):28330-9. PubMed ID: 12011054
[TBL] [Abstract][Full Text] [Related]
27. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P; Gadewal N; De A
Int J Biol Macromol; 2023 Jul; 242(Pt 2):124765. PubMed ID: 37156315
[TBL] [Abstract][Full Text] [Related]
28. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
29. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
Zhang Q; Park E; Kani K; Landgraf R
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13237-42. PubMed ID: 22733765
[TBL] [Abstract][Full Text] [Related]
30. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
[TBL] [Abstract][Full Text] [Related]
31. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
32. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
Claus J; Patel G; Ng T; Parker PJ
Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
[TBL] [Abstract][Full Text] [Related]
33. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
34. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
35. Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Ferreira RB; Law ME; Jahn SC; Davis BJ; Heldermon CD; Reinhard M; Castellano RK; Law BK
Oncotarget; 2015 Apr; 6(12):10445-59. PubMed ID: 25865227
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
Chen CH; Chernis GA; Hoang VQ; Landgraf R
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
[TBL] [Abstract][Full Text] [Related]
37. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.
Diwanji D; Trenker R; Thaker TM; Wang F; Agard DA; Verba KA; Jura N
Nature; 2021 Dec; 600(7888):339-343. PubMed ID: 34759323
[TBL] [Abstract][Full Text] [Related]
38. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.
Maadi H; Nami B; Tong J; Li G; Wang Z
BMC Cancer; 2018 Mar; 18(1):238. PubMed ID: 29490608
[TBL] [Abstract][Full Text] [Related]
39. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
40. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]